Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 15
Submit an article Journal homepage
107
Views
14
CrossRef citations to date
0
Altmetric
Review

Pharmacogenetics of colorectal cancer

Sharon Marsh Division of Oncology, Washington University School of Medicine, 660 South Euclid Ave – Campus Box 8069, St Louis, MO 63110, USA. [email protected]
Pages 2607-2616 | Published online: 30 Nov 2005

Bibliography

  • EVANS WE, RELLING MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 286(5439):487–491.
  • SARGENT DJ, NIEDZWIECKI D, O'CONNELL MJ, SCHILSKY RL: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl. J. Med. (2001) 345(2):144–145.
  • EVANS WE, MCLEOD HL: Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl. J. Med. (2003) 348(0:538–549.
  • WATTERS P(1, MCLEOD HL: Recent advances in the pharmacogenetics of cancer chemotherapy. Curr. Opin. Mol. Ther. (2002) 4(6):565–571.
  • MARSH S, KWOK P, MCLEOD HL: SNP databases and pharmacogenetics: great start, but a long way to go. Hum. Mutat. (2002) 20(3):174–179.
  • WHEELER DL, BARRETT T, BENSON DA et al.: Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. (2005) 33:D39–D45.
  • KWOK PY: Methods for genotyping single nucleotide polymorphisms. Ann. Rev. Genomics Hum. Genet. (2001) 2:235–258.
  • FREIMUTH RR, AMEYAW M-M, PRITCHARD SC, KWOK P-Y, MCLEOD HL: High-throughput genotyping methods for pharmacogenomic studies. Current Pharmacogenomics (2004) 2(1):21–33.
  • SYVANEN AC: Toward genome-wide SNP genotyping. Nat. Genet. (2005) 37(Suppl.):55–510.
  • POON Mk O'CONNELL MJ, MOERTEL CG et al.: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol. (1989) 7(141407–1418.
  • SALTZ LB, COX JV, BLANKE C et ell.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N EngL J. Med. (2000) 343(13):905–914.
  • GOLDBERG RM, SARGENT DJ, MORTON RF et aL: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. (2004) 22(1):23–30.
  • ••Randomised trial comparingcombinations of irinotecan, oxaliplatin and 5-fluorouracil, including toxicity data.
  • HOFF PM, PAZDUR R: Progress in the development of novel treatments for colorectal cancer. Oncology (2004) 18(6):705–708.
  • HURWITZ HI, FEHRENBACHER L, HAINSWORTH JD et aL: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. (2005) 23(15):3502–3508.
  • CUNNINGHAM D, HUMBLET Y, SIENA S et aL: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N EngL J. Med. (2004) 351(4):337–345.
  • HURWITZ H, FEHRENBACHER L, NOVOTNY W et aL: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N EngL J. Med. (2004) 350(23):2335–2342.
  • SCHRAG D: The price tag on progress-chemotherapy for colorectal cancer. N Engl. J. Med. (2004) 351(4):317–319.
  • HEIDELBERGER C, CHAUDHURI NK, DANNEBERG P et aL: Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature (1957) 179(4561):663–666.
  • MCLEOD HL, KING CR, MARSH S: Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies. Clin. Colorectal Cancer (2004) 4\(Suppl. 1):543–47.
  • JOHNSTON PG, FISHER ER, ROCKETTE HE et aL: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. Clin. Oncol. (1994) 12(12):2640–2647.
  • ••Identifies thymidylate synthase as a markerfor 5-fluorouracil response.
  • JOHNSTON PG, LENZ HJ, LEICHMAN CG et al.: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. (1995) 55(7):1407–1412.
  • LEICHMAN CG, LENZ HJ, LEICHMAN L et aL: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. j Clin. Oncol. (1997) 15(10):3223–3229.
  • SOHN KJ, CROXFORD R, YATES Z, LUCOCK M, KIM YT: Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. NatL Cancer Inst. (2004) 96(2):134–144.
  • VAN KUILENBURG AB, MEINSMA R, ZOETEKOUW L, VAN GENNIP AH: High prevalence of the IV514 + 1G A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics (2002) 12(7):555–558.
  • WEI X, ELIZONDO G, SAPONE A et al.: Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics (1998) 51(3):391–400.
  • EZZELDIN H, JOHNSON MR, OKAMOTO Y, DIASIO R: Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin. Cancer Res. (2003) 9(8):3021–3028.
  • SECK K, RIEMER S, KATES R et al.: Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin. Cancer Res. (2005) 11(161:5886–5892.
  • ZHU AX, PUCHALSKI TA, STANTON VP JR et aL: Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/ leucovorin chemotherapy in colorectal cancer. Clin. Colorectal Cancer (2004) 3(4):225–234.
  • MARSH S, COLLIE-DUGUID ES, LIT, LIU X, MCLEOD HL: Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics (1999) 58(3):310–312.
  • MARSH S, AMEYAW MM, GITHANG'A J et al.: Novel thymidylate synthase enhancer region alleles in African populations. Hum. Mutat. (2000) 16(6):528.
  • HORIE N, MBA H, OGURO K, HOJO H, TAKEISHI K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. (1995) 20(3):191–197.
  • KAWAKAMI K, SALONGA D, PARK JM et al.: Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin. Cancer Res. (2001) 7(12) :4096–4101.
  • MARSH S, MCKAY JA, CASSIDY J, MCLEOD HL: Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int. J. Oncol. (2001) 19(2):383–386.
  • VILLAFRANCA E, OKRUZHNOV Y, DOMINGUEZ MA et al.: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. (2001) 19(6):1779–1786.
  • ••Identifies the thymidylate synthasepromoter enhancer as a genetic marker for the prediction of 5-fluorouracil response.
  • MCLEOD HL, TAN B, MALYAPA R et aL: Genotype-guided neoadjuvant therapy for rectal cancer. Proc. Am. Soc. Clin. OncoL (2005) 23:197.
  • MANDOLA MV STOEHLMACHER J, MULLER-WEEKS S et al.: A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. (2003) 63(11):2898–2904. Discovery of a single nucleotide polymorphism within the thymidylate synthase promoter enhancer region that stratifies thymidylate synthase expression levels for the TSER*3 allele.
  • KAWAKAMI K, WATANABE G: Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res. (2003) 63(106004–6007.
  • MARCUELLO E, ALTES A, DEL RIO E et al.: Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int. J. Cancer (2004) 112(5):733–737.
  • ULRICH CM, BIGLER J, VELICER CM et al.: Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol. Biomarkers Prev. (2000) 9(12):1381–1385.
  • MANDOLA MV STOEHLMACHER J, ZHANG W et al.: A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics (2004) 14(5):319–327.
  • ETIENNE MC, ILC K, FORMENTO JL et al.: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. Br. J. Cancer (2004) 90(2):526–534.
  • ETIENNE MC, FORMENTO JL, CHAZAL M et al.: Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics (2004) 14(12):785–792.
  • CHARASSON V, BELLOTT R, MEYNARD D et al.: Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin. Pharmacol Ther. (2004) 76(6):528–535.
  • WU MH, CHEN P, WU X et ell.: Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene. Pharmacogenetics (2004) 14(9):595–605.
  • MARSH S, XIAO M, YU J et al.: Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics (2004) 84(4):661–668.
  • SANTOS A, ZANETTA S, CRESTEIL T et al.: Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin. Cancer Res. (2000) 6(5):2012–2020.
  • HUSTERT E, ZIBAT A, PRESECAN-SIEDEL E et al.: Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos. (2001) 29(11):1454–1459.
  • MARCUELLO E, ALTES A, MENOYO A et al.: UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer (2004) 91(4):678–682.
  • INNOCENTI F, UNDEVIA SD, IYER L et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. j Clin. Oncol. (2004) 22(8):1382–1388.
  • ••Prospective study defining UGT1A1*28 asa genetic marker for irinotecan toxicity.
  • SPARREBOOM A, DANESI R, ANDO Y, CT-JAN J, FIGG WD: Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Updat. (2003) 6(2):71–84.
  • STRASSBURG CP, NGUYEN N, MANNS MP, TUKEY RH: UDP-glucuronosyltransferase activity in human liver and colon. Gastroenterology (1999) 116(1):149–160.
  • BOSMA PJ, CHOWDHURY JR, BAKKER C et al.: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl. J. Med. (1995) 333(18):1171–1175.
  • BEUTLER E, GELBART T, DEMINA A: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl. Acad. Sci. USA (1998) 95(108170–8174.
  • CECCHIN E, RUSSO A. CORONA G et al.: UGT1A1*28 polymorphism in ovarian cancer patients. Oncol. Rep. (2004) 12(2):457–462.
  • IYER L, HALL D, DAS S et ell.: Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. PharmacoL Ther. (1999) 65(5):576–582.
  • ZHOU Q, SPARREBOOM A, TAN EH et al.: Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br. J. Clin. Pharmacol (2005) 59(4):415–424.
  • HORIKAWA M, KATO Y, TYSON CA, SUGIYAMA Y: The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab. Pharmacokinet. (2002) 17(1):23–33.
  • SCHELLENS JH, MALIEPAARD M, SCHEPER RJ et al.: Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann. NY Acad. Sci. (2000) 922:188–194.
  • CANDEIL L, GOURDIER I, PEYRON D et al.: ABCG2 overexpression in colon cancer cells resistant to 5N38 and in irinotecan-treated metastases. Int. J. Cancer (2004) 109(6):848–854.
  • DEAN M, HAMON Y, CHIMINI G: The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. (2001) 42(7):1007–1017.
  • MATHIJSSEN RH, MARSH S, KARLSSON MO et al.: Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin. Cancer Res. (2003) 9(9):3246–3253.
  • SAI K, KANIWA N, ITODA M et al.: Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics (2003) 13(12):741–757.
  • HORIKAWA M, KATO Y, SUGIYAMA Y: Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm. Res. (2002) 19(9):1345–1353.
  • INNOCENTI F, UNDEVIA SD, CHEN PX et al.: Pharmacogenetic analysis of interindividual irinotecan (CPT-11) pharmacokinetic (PK) variability: evidence for a functional variant of ABCC2. Proc. Am. Assoc. Clin. Oncol. (2004) 23:129.
  • INNOCENTI F, UNDEVIA SD, ROSNER GL et al.: Irinotecan (CPT-11) pharmacokinetics (PK) and neutropenia: interaction among UGT1A1 and transporter genes. Proc. Am. Soc. Clin. Oncol. (2005) 23:136s.
  • IMAI Y, NAKANE M, KAGE K et ell.: C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. MoL Cancer Ther. (2002) 1(8):611–616.
  • DE JONG FA, MARSH S, MATHIJSSEN RH et aL: ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res. (2004) 10(17):5889–5894.
  • SPARREBOOM A. GELDERBLOM H, MARSH S et al.: Diflomotecan Pharmacokinetics in relation to ABCG2 421C A genotype. Clin. PharmacoL Ther. (2004) 76(1):38–44.
  • SAMIMI G, SAFAEI R, KATANO K et ell.: Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin. Cancer Res. (2004) 10(14):4661–4669.
  • NAKAYAMA K, KANZAKI A. TERADA K et al.: Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy. Clin. Cancer Res. (2004) 10(8):2804–2811.
  • SAFAEI R, HOWELL SB: Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit. Rev. Oncol. HematoL (2005) 53(1):13–23.
  • STOEHLMACHER J, PARK DJ, ZHANG W et al.: Association between glutathione S-transferase P1, Ti, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl. Cancer Inst. (2002) 94(12):936–942.
  • GROTHEY A, MCLEOD HL, GREEN EM et al.: Glutathione S-transferase P1 1105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity. Proc. Am. Assoc. Clin. Oncol. (2005) 23:248.
  • RYU JS, HONG YC, HAN HS et aL: Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer (2004) 44(3):311–316.
  • ISLA D, SARRIES C, ROSELL R et al.: Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. (2004) 15(8):1194–1203.
  • STOEHLMACHER J, PARK DJ, ZHANG W et al.: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br. J. Cancer (2004) 91(2):344–354. Polygenic approach to colorectal cancer pharmacogenetics.
  • VIGUIER J, BOIGE V, MIQUEL C et al.: ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin. Cancer Res. (2005) 11(17):6212–6217.
  • PARK DJ, STOEHLMACHER J, ZHANG W et al.: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. (2001) 61(24):8654–8658.
  • SEKER H, BUTKIEWICZ D, BOWMAN ED et al.: Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. Cancer Res. (2001) 61(20):7430–7434.
  • GURUBHAGAVATULA S, LIU G, PARK S et al.: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. (2004) 22(13):2594–2601.
  • MORONI M, VERONESE S, BEN VENUTI S et al.: Gene copy number for epidermal growth factor receptor (EGER) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. (2005) 6(5):279–286.
  • VALLBOHMER D, ZHANG W, GORDON M et al.: Molecular determinants of cetuximab efficacy. Clin. Oncol. (2005) 23(15):3536–3544.
  • MCLEOD HL: Drug pathways: movingbeyond single gene pharmacogenetics. Pharmacogenomics (2004) 5(2):139–141.
  • MCLEOD HL, MARSH S: Pharmacogenetics goes 3D. Nat. Genet. (2005) 37(8):794–795. Websites

Websites

  • http://cancerresearchuk.org/aboutcancer/ statistics/ Cancer Research UK. Accessed 8 November, 2005.
  • http://www.cancer.org/docroot/PRO/ content/ PRO 1 1 Cancer_Statistics_2005_Present ation.asp American Cancer Society. Accessed 8 November, 2005.
  • http://www.jr2.ox.ac.uk/bandolier/ Extraforbando/ADRPM.pdf WIFFEN P, GILL M, EDWARDS J, MOORE A: Adverse drug reactions in hospital patients: a systematic review of the prospective and retrospective studies. Bandolier Extra (2002). Accessed 8 November, 2005.
  • http://www.fda.gov/bbs/topics/NEWS/ 192005/NEW01220.html FDA press release 22 August, 2005. Accessed 31 October, 2005.
  • http://pharmacogenetics.wustl.edu CREATE Pharmacogenetics Research Network. Accessed 31 October, 2005.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.